Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer

Summary

To evaluate the efficacy of SR31747 given at 75 or 125mg per day versus placebo in androgen prostate cancer patient without distant metastases with Time to Clinical progression as main objective and PSA parameters, Tumor response, survival , safety,Tumor-related symptoms deterioration Quality of Life, PK analysis as secondary objectives

Timeline

Start

2003-10

Primary completion

2006-08

Completion

2006-08

Drugs

Indications